IL162314A0 - Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition - Google Patents
Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibitionInfo
- Publication number
- IL162314A0 IL162314A0 IL16231402A IL16231402A IL162314A0 IL 162314 A0 IL162314 A0 IL 162314A0 IL 16231402 A IL16231402 A IL 16231402A IL 16231402 A IL16231402 A IL 16231402A IL 162314 A0 IL162314 A0 IL 162314A0
- Authority
- IL
- Israel
- Prior art keywords
- dicarboxylic acid
- acid diamides
- pyrimidine
- pyridine
- andof
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10160357A DE10160357A1 (de) | 2001-12-08 | 2001-12-08 | Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen |
| PCT/EP2002/013240 WO2003049738A1 (de) | 2001-12-08 | 2002-11-25 | Verwendung von pyridin-2,4-dicarbonsäurediamiden und pyrimidin-4,6-dicarbonsäurediamiden zur selektiven inhibierung von kollagenasen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162314A0 true IL162314A0 (en) | 2005-11-20 |
Family
ID=7708512
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16231402A IL162314A0 (en) | 2001-12-08 | 2002-11-25 | Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition |
| IL162314A IL162314A (en) | 2001-12-08 | 2004-06-02 | Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides, processes for their preparation, pharmaceutical compositions comprising them and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL162314A IL162314A (en) | 2001-12-08 | 2004-06-02 | Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides, processes for their preparation, pharmaceutical compositions comprising them and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1455790B1 (xx) |
| JP (1) | JP4527980B2 (xx) |
| AT (1) | ATE390137T1 (xx) |
| AU (1) | AU2002358535B2 (xx) |
| CA (1) | CA2469625C (xx) |
| DE (2) | DE10160357A1 (xx) |
| IL (2) | IL162314A0 (xx) |
| MX (1) | MXPA04005129A (xx) |
| WO (1) | WO2003049738A1 (xx) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2002000328A (es) | 2001-02-14 | 2003-08-30 | Warner Lambert Co | Pirimidinas inhibidoras de metaloproteinasas de matriz |
| DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| JP4164028B2 (ja) | 2001-10-12 | 2008-10-08 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アルキンマトリックスメタロプロテイナーゼ阻害剤 |
| KR101050680B1 (ko) * | 2002-11-02 | 2011-07-21 | 사노피-아벤티스 도이칠란트 게엠베하 | 콜라게네이즈의 선택적인 억제를 위한 신규한피리미딘-4,6-디카복스아미드 |
| DE10300017A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Selektive MMP 13 Inhibitoren |
| US20060173183A1 (en) * | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| KR20080087070A (ko) * | 2005-05-20 | 2008-09-30 | 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 | 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제 |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| WO2008002671A2 (en) * | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| WO2009140101A2 (en) * | 2008-05-12 | 2009-11-19 | Boehringer Ingelheim International Gmbh | Imidazopyridine compounds useful as mmp-13 inhibitors |
| GB201908453D0 (en) * | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3931432A1 (de) * | 1989-09-21 | 1991-04-04 | Hoechst Ag | Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen |
| DE4020570A1 (de) * | 1990-06-28 | 1992-01-02 | Hoechst Ag | 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung |
| DOP2002000333A (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
| DOP2002000328A (es) * | 2001-02-14 | 2003-08-30 | Warner Lambert Co | Pirimidinas inhibidoras de metaloproteinasas de matriz |
| DOP2002000332A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
-
2001
- 2001-12-08 DE DE10160357A patent/DE10160357A1/de not_active Withdrawn
-
2002
- 2002-11-25 AU AU2002358535A patent/AU2002358535B2/en not_active Ceased
- 2002-11-25 WO PCT/EP2002/013240 patent/WO2003049738A1/de active IP Right Grant
- 2002-11-25 CA CA2469625A patent/CA2469625C/en not_active Expired - Fee Related
- 2002-11-25 MX MXPA04005129A patent/MXPA04005129A/es active IP Right Grant
- 2002-11-25 EP EP02792799A patent/EP1455790B1/de not_active Expired - Lifetime
- 2002-11-25 AT AT02792799T patent/ATE390137T1/de not_active IP Right Cessation
- 2002-11-25 IL IL16231402A patent/IL162314A0/xx unknown
- 2002-11-25 JP JP2003550787A patent/JP4527980B2/ja not_active Expired - Fee Related
- 2002-11-25 DE DE50211985T patent/DE50211985D1/de not_active Expired - Lifetime
-
2004
- 2004-06-02 IL IL162314A patent/IL162314A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005513049A (ja) | 2005-05-12 |
| ATE390137T1 (de) | 2008-04-15 |
| IL162314A (en) | 2011-07-31 |
| CA2469625A1 (en) | 2003-06-19 |
| DE50211985D1 (de) | 2008-05-08 |
| CA2469625C (en) | 2011-07-26 |
| DE10160357A1 (de) | 2003-06-18 |
| EP1455790B1 (de) | 2008-03-26 |
| WO2003049738A1 (de) | 2003-06-19 |
| AU2002358535B2 (en) | 2007-05-10 |
| AU2002358535A1 (en) | 2003-06-23 |
| JP4527980B2 (ja) | 2010-08-18 |
| EP1455790A1 (de) | 2004-09-15 |
| MXPA04005129A (es) | 2004-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200200068T2 (tr) | Nematisital triflüorobütenler | |
| BG104599A (en) | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | |
| RS50091B (sr) | Upotreba retigabina u lečenju neuropatskog bola | |
| RS20050199A (xx) | Imidazolopiridini i postupci za njihovo dobijanje i upotrebu | |
| BG105783A (en) | Triazole compounds with dopamine-d3-receptor affinity | |
| BG106586A (en) | Pyrazolopyramidines as therapeutic agents | |
| MY135766A (en) | Quinolinones and naphthyridinones for treating inflammatory diseases | |
| IL162314A0 (en) | Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition | |
| HRP20050382A2 (en) | Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases | |
| BG103096A (en) | Thrombin inhibitors | |
| NO972391D0 (no) | 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav | |
| MY115211A (en) | Novel amino acid derivatives, their preparation and use | |
| NZ332096A (en) | Alpha-hydroxylic acid derivatives their production and use in treating conditions requiring endothelin inhibition | |
| MXPA04004372A (es) | Derivados heterociclicos de glicinamida y su uso medico. | |
| SI1173439T1 (en) | Haloalkoxy imidazonaphthyridines | |
| BG106008A (en) | Novel lhrh antagonists with improved solubility characteristics | |
| ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
| AP2000001761A0 (en) | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase. | |
| MXPA02012263A (es) | 5-aminoalquil-pirazol[4,3-d]pirimidinas. | |
| TW200505906A (en) | Selective mmp-13 inhibitors | |
| HUP0202729A2 (hu) | Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények | |
| BR0010560A (pt) | 3-piridil-4-arilpirrois substituìdos e métodos terapêuticos e profiláticos relacionados | |
| MXPA02012260A (es) | 2-aminoalquil-tieno[2,3-d]pirimidinas. | |
| PL345966A1 (en) | N-substituted azabicycloheptane derivatives, production and use thereof | |
| HK1048473A1 (zh) | 取代的2-芳基-1，2，4-三嗪-3，5-二(硫)酮 |